Dupilumab Reduced Exacerbations and Improved Lung Function and Asthma Control in Children With Uncontrolled, Moderate-to-Severe Asthma and Baseline High/Medium ICS Dose

Jorge F. MASPERO, Fundacion Cidea, Buenos Aires, Buenos Aires, Argentina; Martti A. Antila, CMPC Pesquisa Clinica/Clin de Alergia Martti AnTIL, Sorocaba, Sao Paulo, Brazil; Leonard B. Bacharier, Division of Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr Children’s Hospital at Vanderbilt University Medical Center, Nashville, TN, United States; Arman Altincatal, Sanofi, Cambridge, MA, United States; Elizabeth Laws, Sanofi, Cambridge, MA, United States; Eric R. Mortensen, Regeneron Pharmaceeuticals, White Plains, NY, United States; Amr Radwan, Regeneron, Uxbridge, England, United Kingdom; Juby Anne. Jacob-Nara, Sanofi, Hillsborough, NJ, United States; Yamo Deniz, Regeneron Pharmaceuticals, Naples, FL, United States; Paul J Rowe, Sanofi, Bridgewater, NJ, United States; David J. Lederer, Regeneron Pharmaceuticals, Tarrytown, NY, United States; Erik Orava, Sanofi, Mississauga, ON, Canada; Megan Hardin, Sanofi, Cambridge, MA, United States